11 IPOs Scheduled for Week of Feb. 2 to Raise $1.44 billion

Francis Gaskins |

Wall_Street.jpgThere are 11 IPOs set to begin trading for the week of February 2, 2015. 

IPO Calendar with recommendations/reports HERE

(1) Based in Houston, TX, Columbia Pipeline Partners LP (CPPL) scheduled an expected $800 million IPO on the NYSE with a market capitalization of $800 million at a price range midpoint of $20 for Friday, Feb. 6, 2015.

CPPL is a fee-based, growth-oriented Delaware limited partnership formed by NiSource (NYSE: NI) $13.4 billion market cap) to own, operate and develop a portfolio of natural gas pipelines, storage and related midstream assets.

Compare with parent NiSource (NI), EQT Midstream Partners LP (EQM) and Dominion Transmission (D).

(2) Based in Washington, D.C.,Easterly Government Properties (DEA) scheduled a $180 million IPO on the NYSE with a market capitalization of $570 million at a price range midpoint of $15 for Friday, Feb. 6, 2015.

DEA is a newly organized and internally managed Maryland corporation that intends to qualify as a real estate investment trust, or REIT, focused primarily on the acquisition, development and management of Class A commercial properties that are leased to U.S. Government agencies that serve essential functions.

Compare with City Office REIT (CIO), Lexington Realty Trust (LXP), Boston Properties (BXP).

(3) Based in Saint Genis Pouilly, France, Advanced Accelerator Applications S.A. (AAAP) scheduled a $75 million IPO on the Nasdaq with a market capitalization of $518 million at a price range midpoint of $14 for Thursday, Feb. 5, 2015.

AAAP is an innovative radiopharmaceutical company that develops, produces and commercializes MNM diagnostic and therapeutic products.

MNM is a medical specialty that uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases such as cancer.

29% top line rev growth to $59mm for Sept 9 mos. Therapeutic candidate could begin Phase 3 trial by end of '15.

(4) Based in Palo Alto, CA, Carbylan Therapeutics (CBYL) scheduled a $75 million IPO on the Nasdaq with a market capitalization of $198 million at a price range midpoint of $13 for Wednesday, Feb. 4, 2015.

CBYL is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel and proprietary combination therapies that address significant unmet medical needs.

CBYL’s initial focus is on the development of Hydros-TA, its proprietary, potentially best-in-class intra-articular, or IA, injectable product candidate to treat pain associated with osteoarthritis, or OA, of the knee.



(5) Based in Lexington, MA, Inotek Pharmaceuticals (ITEK) scheduled a $65 million IPO on the Nasdaq with a market capitalization of $191 million at a price range midpoint of $14 for Thursday, Feb. 5, 2015.

ITEK is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma.

Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP.

ITEK’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic that ITEK rationally designed to lower IOP by restoring the eye’s natural pressure control mechanism.

(6) Based in San Diego, CA, AltheaDx (IDGX) scheduled a $60 million IPO on the Nasdaq with a market capitalization of $161 million at a price range midpoint of $13 for Wednesday, Feb. 4, 2015.

IDGX is a IDGX is a commercial stage molecular diagnostics company specializing in the field of personalized medicine.

IDgenetix, IDGX’s pharmacogenetic, or PGx, testing portfolio, enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain.

IDgenetix may reduce health care costs

(7) Based in Dublin, Ireland, Nexvet Biopharma plc (NVET) scheduled a $58 million IPO on the Nasdaq with a market capitalization of $160 million at a price range midpoint of $14.50 for Thursday, Feb. 5, 2015.

NVET is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics based on human biologics.

As a class, biologics, which include mAbs and fusion proteins, have transformed human medicine in recent decades and represent some of the top-selling therapies on the market today.

Veterinary care is one of the fastest growing industries in the overall U.S. companion animal market and is estimated to reach $15.3 billion in 2014.

(8) Based in Sunnyvale, CA, Asante Solutions (PUMP) scheduled a $49 million IPO on the Nasdaq with a market capitalization of $167 million at a price range midpoint of $14 for Thursday, Feb. 5, 2015.

PUMP is a medical device company with the mission of improving and simplifying the management of diabetes patients and healthcare practitioners.

(9) Based in Mount Carmel, Israel, Check-Cap Ltd. (CHEK) scheduled a $13 million IPO on Nasdaq with a market capitalization of $91 million at a price range midpoint of $11 for Friday, Feb. 6, 2015.

CHEK is a clinical stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for colorectal cancer (CRC) screening.

Holdovers

(a) Based in Burlington, MA, Infraredx (REDX) scheduled a $56 million IPO on the Nasdaq with a market capitalization of $199 million at a price range midpoint of $14 for Wednesday, Feb 4, 2015.
 

(b) Based in Waltham, MA, EyeGate Pharmaceuticals (EYEG) scheduled a $7.8 million IPO on the Nasdaq with a market capitalization of $48 million at a price range midpoint of $7 for  the week of February 2, 2015..

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
ITEK Inotek Pharmaceuticals Corporation 2.33 0.03 1.30 1,325,016 Trade
CBYL Carbylan Therapeutics Inc. n/a n/a n/a n/a
DEA Easterly Government Properties Inc. 20.63 -0.13 -0.63 162,646 Trade
CPPL Columbia Pipeline Partners LP representing Limited n/a n/a n/a 0 Trade
CHEK Check-Cap Ltd. 1.68 -0.03 -1.66 18,496 Trade
NVET Nexvet Biopharma plc n/a n/a n/a 0 Trade
EYEG Eyegate Pharmaceuticals Inc. 1.11 -0.00 -0.21 63,960 Trade

Comments

Emerging Growth

Taranis Resources Inc.

Taranis Resources Inc is an exploration stage company. The Company along with its subsidiaries is engaged in the acquisition and exploration of mineral properties. Its projects include Thor Property in…

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…